Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$35.5M | -$54.2M | -$89.6M | -$104M | -$232M | -$468M | -$570M | -$924M |
| Net income | -$29.5M | -$50.3M | -$89.2M | -$100M | -$223M | -$402M | -$464M | -$767M |
| EPS (diluted) | -$8.12 | -$13.25 | -$3.02 | -$1.93 | -$3.44 | -$4.14 | -$3.80 | -$5.63 |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$30.5M | -$47.1M | -$46.6M | -$121M | -$171M | -$297M | -$453M | -$656M |
| Capital expenditures | $1.77M | $1.20M | $1.16M | $6.55M | $5.84M | $16.1M | $22.4M | $13.7M |
| Free cash flow | -$32.2M | -$48.3M | -$47.8M | -$128M | -$176M | -$313M | -$475M | -$669M |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $66.1M | $59.0M | $386M | $69.0M | $835M | $397M | $388M | $174M |
| Total assets | — | $65.7M | $393M | $324M | $1.01B | $1.41B | $3.51B | $3.00B |
| Total liabilities | — | $11.8M | $47.0M | $40.3M | $52.6M | $167M | $205M | $317M |
| Shareholders' equity | -$57.7M | -$106M | $346M | $284M | $954M | $1.24B | $3.31B | $2.69B |
| Retained earnings | — | -$109M | -$199M | -$299M | -$522M | -$924M | -$1.39B | -$2.15B |
| Shares (wtd avg diluted) | — | 4.06M | 29.5M | 51.9M | 64.9M | 97.2M | 122M | 136M |
Every figure is extracted from Vaxcyte, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.